OnKure Therapeutics, Inc. beat EPS estimates 67% of the time across 3 reported quarters (2 beats, 1 misses), averaging +7.8% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.58 | $-0.31 | +46.5% | Beat | |
| Q1 FY26 | $-0.81 | $-1.11 | -37.0% | Miss | |
| Q4 FY25 | $-1.15 | $-0.99 | +13.9% | Beat |
Back to OKUR overview · OKUR holders · OKUR KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.